Conferences

December 02, 2024

The American Society of Hematology's annual conference is a significant event for the blood cancer community, including those involved in AML research.

July 16, 2024

Dr. Voso shared insight about the experiences of patients whose MDS transformed into AML taking oral azacitidine as a maintenance therapy.

July 02, 2024

Dr. El-Jawahri shared how palliative care can improve AML patients’ quality of life and better prepare them for potential end-of-life care plans.

June 26, 2024

Dr. Ohanian shared findings about how the treatment combination of prexigebersen, venetoclax, and decitabine helped AML patients in a clinical trial.

June 19, 2024

Dr. Kebriaei assessed if CD33-positive AML patients receiving gemtuzumab before allogeneic stem cell transplant face a higher risk of liver side effects.

June 17, 2024

Understanding the role of stem cell transplants in cancer treatment: Insights from recent data and considerations for patient-specific decisions

June 13, 2024

Dr. Bazinet shared insight about the benefits frail AML patients may receive from shortening the venetoclax + HMA treatment cycle.

May 27, 2024

The American Society of Clinical Oncology holds a yearly conference in June to allow researchers and doctors in the cancer community an opportunity to share…

May 21, 2024

Dr. Amy DeZern shared how the medicine tamibarotene is helping high-risk MDS and AML patients with an overexpressed RARA gene in their cancer cells.

February 26, 2024

Dr. Desai shares information about the latest maintenance therapies being used in AML treatment: Gilteritinib and quizartinib.